Sanofi and GlaxoSmithKline Delay COVID-19 Vaccine Program Due to Poor Immune Response in Older Adults
Two of the world's leading vaccine manufacturers have run into a big problem with their joint coronavirus vaccine program. Lackluster immune responses from some of the first patients injected with a candidate developed by Sanofi (NASDAQ: SNY) and GlaxoSmithKline (NYSE: GSK) led the partners to announce on Friday morning that they were delaying the phase 3 trial that they'd planned to start this month.
Interim results from the companies' phase 1/2 clinical trial showed the original vaccine formulation generated sufficient immune responses in volunteers aged 18 to 49. Unfortunately, the immune responses it produced in older adults were lower than levels seen among patients who have successfully recovered from COVID-19.
Image source: Getty Images.
Source Fool.com
